Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/bevacizumab-Tj3injnaYG
References (28)
-
O. Melnyk, M. Zimmerman, K.J. Kim (1999)
Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical modelJ Urol, 161
-
M.S. Gordon, K. Margolin, M. Talpaz (2001)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancerJ Clin Oncol, 19
-
R.S. Warren, H. Yuan, M.R. Matli (1995)
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasisJ Clin Invest, 95
-
K. Margolin, M.S. Gordon, E. Holmgren (2001)
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety dataJ Clin Oncol, 19
-
H.-P. Gerber, J. Kowalski, D. Sherman (2000)
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factorCancer Res, 60
-
R. Midgley, D. Kerr (1999)
Colorectal cancerLancet, 353
-
D.M. Parkin (2001)
Global cancer statistics in the year 2000Lancet Oncol, 2
-
P. Borgström, K.J. Hillan, P. Sriramarao (1996)
Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopyCancer Res, 56
-
J. Gaudreault, G. Lieberman, F. Kabbinavar (2001)
Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer (CRC) [abstract no. PI-98]Clin Pharmacol Ther, 69
-
Kim Kj, Bing Li, K. Houck, J. Winer, N. Ferrara (1992)
The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.Growth factors, 7 1
-
F. Yuan, Y. Chien, M. Dellian (1996)
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibodyProc Natl Acad Sci USA, 93
-
A. Young, D. Rea (2000)
ABC of colorectal cancer: treatment of advanced diseaseBMJ, 321
-
F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher (2003)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerJ Clin Oncol, 21
-
A. Jemal, T. Murray, A. Samuels (2003)
Cancer statistics, 2003CA Cancer J Clin, 53
-
V. Hsei, P. Siguenza, J. Gaudreault (2002)
Effect of body weight on bevacizumab pharmacokinetics in cynomolgus monkeys and humans [abstract no. 1818]Proc Am Soc Clin Oncol, 21
-
H. Hurwitz, L. Fehrenbacher, W. Novotny (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for the treatment of metastatic colorectal cancerN Engl J Med, 350
-
V. Hsei, G.G. DeGuzman, A. Nixon (2002)
Complexation of VEGF with bevacizumab decreases VEGF clearance in ratsPharm Res, 19
-
J.D. Berlin (2002)
Targeting vascular endothelial growth factor in colorectal cancerOncology, 16
-
P. Boyle, J.S. Langman (2000)
ABC of colorectal cancer: epidemiologyBMJ, 321
-
O. Melnyk, M.A. Shuman, K.J. Kim (1996)
Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growthCancer Res, 56
-
L. Scott, J. Fraser, J. Cassidy (2003)
Emerging drugs in colorectal cancerExpert Opinion on Emerging Drugs, 8
-
L.G. Presta, H. Chen, S.J. OxConnor (1997)
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res, 57
-
Hans Wildiers, G. Guetens, G. Boeck, Erik Verbeken, Bart Landuyt, Willy Landuyt, E. Bruijn, A. Oosterom (2003)
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11British Journal of Cancer, 88
-
J. Lee, N. Chow, Shan-T Wang, Shih-Ming Huang (2000)
Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.European journal of cancer, 36 6
-
V.C. Hsei, W.F. Novotny, K. Margolin (2001)
Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects [abstract no. 272]Proc Am Soc Clin Oncol, 20
-
C.-G. Lee, M. Heijn, E. Tomaso (2000)
Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditionsCancer Res, 60
-
P. Manley, G. Martiny-Baron, J. Schlaeppi, J. Wood (2002)
Therapies directed at vascular endothelial growth factorExpert Opinion on Investigational Drugs, 11
-
K.J. Kim, B. Li, J. Winer (1993)
Inhibition of vascular endothelial growth factor- induced angiogenesis suppresses tumor growth in vivoNature, 362
- Publisher
- Springer Journals
- Copyright
- Copyright © 2004 by Adis Data Information BV
- Subject
- Pharmacy; Pharmacy
- ISSN
- 1175-6357
- DOI
- 10.2165/00024669-200403030-00005
- Publisher site
- See Article on Publisher Site
Abstract
▴ Bevacizumab, a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor, inhibits tumor angiogenesis and delays disease progression.
Journal
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012